|
|
| | PG 97-269 Basic information |
| Product Name: | PG 97-269 | | Synonyms: | PG 97-269;Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27);Ac-His-D-Phe-Asp-Ala-Val-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Lys-Arg-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-NH2;Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27) trifluoroacetate salt Ac-His-D-Phe-Asp-Ala-Val-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Lys-Arg-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-NH2 trifluoroacetate salt;Acetyl-(D-Phe2,Lys1?,Arg1?,Leu2?)-VIP (1-7)-GRF (8-27);L-Leucinamide, N-acetyl-L-histidyl-D-phenylalanyl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-lysyl-L-arginyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-;Acetyl-(D-Phe?,Lys??,Arg??,Leu??)-VIP (1-7)-GRF (8-27) trifluoroacetate salt;Acetyl-(D-Phe2,Lys1?,Arg1?,Leu2?)-VIP (1-7)-GRF (8 | | CAS: | 202463-00-1 | | MF: | C150H246N44O38 | | MW: | 3273.83 | | EINECS: | | | Product Categories: | | | Mol File: | 202463-00-1.mol |  |
| | PG 97-269 Chemical Properties |
| density | 1.42±0.1 g/cm3(Predicted) | | form | Solid | | color | White to off-white | | Sequence | Ac-His-{d-Phe}-Asp-Ala-Val-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Lys-Arg-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-NH2 |
| | PG 97-269 Usage And Synthesis |
| Uses | Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27), a vasoactive intestinal peptide (VIP), is a VIP1 antagonist[1]. | | References | [1] M G Juarranz, et al. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation. Eur J Biochem. 1999 Oct 1;265(1):449-56. DOI:10.1046/j.1432-1327.1999.00769.x |
| | PG 97-269 Preparation Products And Raw materials |
|